PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-95.21%
Negative revenue growth while AVXL stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-116.81%
Negative gross profit growth while AVXL is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
-52.01%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-52.01%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-52.47%
Negative net income growth while AVXL stands at 4.09%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-43.48%
Negative EPS growth while AVXL is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-43.48%
Negative diluted EPS growth while AVXL is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
7.17%
Share count expansion well above AVXL's 0.33%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.17%
Diluted share count expanding well above AVXL's 0.33%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
582.93%
Positive OCF growth while AVXL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
577.68%
Positive FCF growth while AVXL is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9508.05%
Positive long-term OCF/share growth while AVXL is negative. John Neff would see a structural advantage in sustained cash generation.
131.96%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
210.81%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
88.12%
Positive 10Y CAGR while AVXL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
91.00%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
67.11%
3Y net income/share CAGR above 1.5x AVXL's 19.43%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1963.85%
10Y equity/share CAGR above 1.5x AVXL's 565.97%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-27.97%
Negative 5Y equity/share growth while AVXL is at 282.38%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
5.99%
Below 50% of AVXL's 563.57%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.35%
Asset growth above 1.5x AVXL's 2.15%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
5.97%
BV/share growth above 1.5x AVXL's 3.65%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
1244.16%
Debt growth of 1244.16% while AVXL is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
6.71%
We increase R&D while AVXL cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
86.34%
We expand SG&A while AVXL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.